Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
M126999-200mg | 200mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $46.90 | |
M126999-1g | 1g | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $151.90 | |
M126999-5g | 5g | In stock | $402.90 | |
M126999-25g | 25g | In stock | $1,409.90 |
PR and GR antagonist
Synonyms | RU486 | RU 38486 | 11β-[4-(Dimethylamino)phenyl]-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one |
---|---|
Specifications & Purity | ≥98% |
Storage Temp | Store at 2-8°C |
Shipped In | Wet ice |
Grade | Moligand™ |
Action Type | AGONIST, ANTAGONIST |
Mechanism of action | Progesterone receptor antagonist |
Product Description | Mifepristone is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. |
ALogP | 3.8 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one |
---|---|
INCHI | InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1 |
InChi Key | VKHAHZOOUSRJNA-GCNJZUOMSA-N |
Canonical SMILES | CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O |
Isomeric SMILES | CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O |
WGK Germany | 3 |
RTECS | KG2955000 |
PubChem CID | 55245 |
Molecular Weight | 429.59 |
Reaxy-Rn | 5779404 |
DrugBank Ligand | DB00834 |
---|---|
PubChem CID | 55245 |
BindingDB Ligand | 18627 |
Wikipedia | Mifepristone |
CAS Registry No. | 84371-65-3 |
ChEMBL Ligand | CHEMBL1276308 |
ChEBI | CHEBI:50692 |
NURSA Ligand | 10.1621/ST5A19ZOKW |
RCSB PDB Ligand | 486 |
PEP | mifepristone |
DrugCentral Ligand | 1805 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
I2226309 | Certificate of Analysis | Jul 10, 2024 | M126999 |
I2226306 | Certificate of Analysis | Jul 04, 2024 | M126999 |
G2417847 | Certificate of Analysis | Jun 29, 2024 | M126999 |
G2417853 | Certificate of Analysis | Jun 29, 2024 | M126999 |
G2417854 | Certificate of Analysis | Jun 29, 2024 | M126999 |
G2417855 | Certificate of Analysis | Jun 29, 2024 | M126999 |
G2417856 | Certificate of Analysis | Jun 29, 2024 | M126999 |
I2226305 | Certificate of Analysis | Jul 22, 2022 | M126999 |
L2307160 | Certificate of Analysis | Jul 22, 2022 | M126999 |
Solubility | Soluble in water (partly), DMF (~30 mg/ml), ethanol (50 mg/ml), methanol, and DMSO (86 mg/ml at 25 °C).(Soluble): chloroform |
---|---|
Sensitivity | Heat sensitive |
Specific Rotation[α] | 141° (C=0.5,CHCl3) |
Melt Point(°C) | 195 °C |
Pictogram(s) | GHS08, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H302:Harmful if swallowed H312:Harmful in contact with skin H332:Harmful if inhaled H360:May damage fertility or the unborn child H362:May cause harm to breast-fed children |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P271:Use only outdoors or in a well-ventilated area. P270:Do not eat, drink or smoke when using this product. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P362+P364:Take off contaminated clothing and wash it before reuse. P330:Rinse mouth. P263:Avoid contact during pregnancy/while nursing. P203:Obtain, read and follow all safety instructions before use. P301+P317:IF SWALLOWED: Get medical help. P318:if exposed or concerned, get medical advice. P317:Get emergency medical help. |
WGK Germany | 3 |
RTECS | KG2955000 |
Reaxy-Rn | 5779404 |
Merck Index | 6186 |
Starting at $47.90
1. Qi-qiang Zhang, Xue-mei Di, Xiang Cao, Yonghong Nie, Wen Shuai, Jun Li, Hai Zhang. (2023) Analysis of pharmacodynamic components, targets and synergistic action mechanism of Fuyuan Shenghua granule for the treatment of medical-induced incomplete abortion based on network pharmacology. JOURNAL OF ETHNOPHARMACOLOGY, (117118). [PMID:37659757] |
2. Sheng Hu, Pei Shen, Bin Chen, Shao-Wen Tian, Yong You. (2022) Apelin-13 reduces lipopolysaccharide-induced neuroinflammation and cognitive impairment via promoting glucocorticoid receptor expression and nuclear translocation. NEUROSCIENCE LETTERS, 788 (136850). [PMID:36038029] |
3. Mengru Bai, Mingyang Chen, Qingquan Zeng, Shuanghui Lu, Ping Li, Zhiyuan Ma, Nengming Lin, Caihong Zheng, Hui Zhou, Su Zeng, Dongli Sun, Huidi Jiang. (2022) Up-regulation of hepatic CD36 by increased corticosterone/cortisol levels via GR leads to lipid accumulation in liver and hypertriglyceridaemia during pregnancy. BRITISH JOURNAL OF PHARMACOLOGY, 179 (17): (4440-4456). [PMID:35491243] |
1. Shannon S et al.. (2015) Dexamethasone-Mediated Activation of Fibronectin Matrix Assembly Reduces Dispersal of Primary Human Glioblastoma Cells.. PLoS One, 10 (8): (e0135951). [PMID:26284619] |
2. Nair M et al.. (2018) Dexamethasone-Mediated Upregulation of Calreticulin Inhibits Primary Human Glioblastoma Dispersal Ex Vivo.. Int J Mol Sci, 19 (2): [PMID:29443896] |
3. Zhang B et al.. (2020) Corticosteroid receptor rebalancing alleviates critical illness-related corticosteroid insufficiency after traumatic brain injury by promoting paraventricular nuclear cell survival via Akt/CREB/BDNF signaling.. J Neuroinflammation, 17 (318). [PMID:33100225] |
4. Wang C et al.. (2017) Experimental research on the relationship between the stiffness and the expressions of fibronectin proteins and adaptor proteins of rat trabecular meshwork cells.. BMC Ophthalmol, 17 (268). [PMID:29284449] |
5. Karami Kheirabad M et al.. (2015) Expression of Melanocortin-4 Receptor mRNA in Male Rat Hypothalamus During Chronic Stress.. Int J Mol Cell Med, 4 (3): (182-7). [PMID:26629487] |
6. Xiao R et al.. (2016) Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype.. Cancer Immunol Res, 4 (6): (488-497). [PMID:27045020] |
7. Qi-qiang Zhang, Xue-mei Di, Xiang Cao, Yonghong Nie, Wen Shuai, Jun Li, Hai Zhang. (2023) Analysis of pharmacodynamic components, targets and synergistic action mechanism of Fuyuan Shenghua granule for the treatment of medical-induced incomplete abortion based on network pharmacology. JOURNAL OF ETHNOPHARMACOLOGY, (117118). [PMID:37659757] |
8. Sheng Hu, Pei Shen, Bin Chen, Shao-Wen Tian, Yong You. (2022) Apelin-13 reduces lipopolysaccharide-induced neuroinflammation and cognitive impairment via promoting glucocorticoid receptor expression and nuclear translocation. NEUROSCIENCE LETTERS, 788 (136850). [PMID:36038029] |
9. Mengru Bai, Mingyang Chen, Qingquan Zeng, Shuanghui Lu, Ping Li, Zhiyuan Ma, Nengming Lin, Caihong Zheng, Hui Zhou, Su Zeng, Dongli Sun, Huidi Jiang. (2022) Up-regulation of hepatic CD36 by increased corticosterone/cortisol levels via GR leads to lipid accumulation in liver and hypertriglyceridaemia during pregnancy. BRITISH JOURNAL OF PHARMACOLOGY, 179 (17): (4440-4456). [PMID:35491243] |